Tag: vitruvias_therapeutics

Vitruvias Therapeutics Recalls Thyroid Tablets Over Super Potency Risk

24 Aug 2026 4:26 p.m. · Source: US Food and Drug Administration

Vitruvias Therapeutics has issued a nationwide recall for one lot of its Thyroid Tablets, USP 30 mg, due to confirmed super potency. This poses a risk of hyperthyroidism, particularly for vulnerable populations like the elderly, pregnant women, and infants.

Health Business Medical Science Legal Product Recall Vitruvias Therapeutics Thyroid Tablets Super Potency Hyperthyroidism Medication Food Recalls FDA Drugs
Vitruvias Therapeutics Recalls Thyroid Tablets Over Super Potency Risk

24 Aug 2026 3:43 p.m. · Source: US Food and Drug Administration

Vitruvias Therapeutics is recalling Thyroid Tablets, USP 30 mg (Lot 504950) nationwide due to potential super potency. This poses a hyperthyroidism risk, especially for vulnerable populations. Patients should consult healthcare providers before discontinuing use.

Health Business Politics and Government Medical Science Federal Government Legal Vitruvias Therapeutics Thyroid Tablets Product Recall Super Potency Hyperthyroidism FDA USA Food Recalls Drugs